A titratable, fixed ratio combination of two well understood and FDA approved peptides to control glycemia while mitigating the threat of hypoglycemia.
The Challenge: Balancing Diabetes Control and Hypoglycemia Risk
Insulin remains the mainstay for glycemic control for patients with Type 1 diabetes and for people with Type 2 diabetes not controlled on non-insulin therapies
Insulin induced hypoglycemia is the primary obstacle to glycemic goal attainment
The majority of patients on insulin do not achieve their A1C targets
~1.4M emergency hospital visits/hospitalizations per year (USA)Severe hypoglycemia occurs at all A1C levels
Severe hypoglycemia and its complications are costly
ABV100: A smart solution that fits well with current and future pharmacological and device platforms.
